In a large retail business group the ID Migraine Screening Test was sent to employees with three or more absences from work in the past year (n = 2893). Employees with positive results were invited for a neurological consultation and migraine patients were randomly assigned to: first attack 'treated as usual' and the second attack treated with 40 mg eletriptan, or reversed order. Of the 2893 employees, 799 responded (28%), 260 were positively screened for migraine (33%), 84 patients were diagnosed by a neurologist and 41 of the 75 included patients completed the protocol. Eletriptan induced pain-free response in 33.3% of the patients at 4 h compared with 0% after 'non-specific' treatment (P = 0.03). Eletriptan also significantly improved quality of life, but differences in absence from work and productivity loss could not be detected. In conclusion, in-company screening can be beneficial for undertreated employees, but implementation obstacles can reduce the effectiveness of screening.

Clinical trial, Cost-effectiveness, Migraine, Netherlands, Productivity, Screening, absenteeism, adult, analgesic agent, article, clinical trial, comparative study, consultation, controlled clinical trial, controlled study, crossover procedure, eletriptan, employee, female, fromirex, human, major clinical study, male, migraine, multicenter study, naratriptan, productivity, quality of life; screening, rizatriptan, screening test, sumatriptan succinate, triptan derivative, unclassified drug, zolmitriptan,
Cephalalgia: an international journal of headache
Erasmus MC: University Medical Center Rotterdam

Mérelle, S.Y.M, Couturier, E.G.M, van Bokhorst, J, van Busschbach, J.J, & Passchier, J. (2009). Large-scale screening and subsequent effects of migraine treatment on the work floor in the Netherlands. Cephalalgia: an international journal of headache, 29(6), 606–615. doi:10.1111/j.1468-2982.2008.01769.x